ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials"
Episode Synopsis
Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of
randomized controlled trials
2023 May;38(4):698-705. doi: 10.1177/02676591221076284.
Abstract
Objective: Ticagrelor may be an alternative to aspirin as it provides
robust and consistent platelet inhibition. However, the effect of ticagrelor
treatment in patients undergoing coronary artery bypass grafting (CABG) has not
been well confirmed. We conducted a meta-analysis to appraise whether ticagrelor
therapy affects outcomes in CABG patients.
Methods: We searched PubMed, Embase, EBSCO, and Cochrane databases from
its inception up to 4 December 2020 for randomized controlled trials that
assessed ticagrelor versus non-ticagrelor in patients undergoing CABG. The
primary outcome was the incidence of saphenous vein graft (SVG) occlusion at 1
year after CABG. Secondary outcomes were SVG occlusion at 7 days, major adverse
cardiovascular events (MACE), and bleeding requiring reoperation.
Results: Seven trials including 4305 patients (2153 randomized to
ticagrelor therapy and 2152 to non-ticagrelor therapy) were included.
One-hundred and thirty of 1140 patients (11.4%) randomized to the ticagrelor
group versus 175 of 1220 patients (14.3%) randomized to the non-ticagrelor
group experienced SVG occlusion at 1 year after CABG. Compared to the control
group, ticagrelor therapy yielded a significantly lower risk of SVG occlusion
[RR 0.79 (0.64-0.97), p = 0.03]. In the subgroup analysis,
ticagrelor plus aspirin compared with aspirin alone did not decrease the risk
of SVG occlusion after 1 year [RR 0.65 (0.40-1.07), p = 0.09].
There was no difference in the incidence of SVG occlusion at 7 days [RR 0.67
(0.42-1.06), p = 0.09], MACE up to 1 year [RR 0.99 (0.81-1.21), p =
0.90], or bleeding requiring reoperation [RR 1.16 (0.80-1.70), p =
0.44].
Conclusions: Compared with non-ticagrelor therapy, ticagrelor decreased the
risk of saphenous vein graft occlusion after 1 year in patients undergoing
elective CABG with saphenous vein grafting.
Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.
randomized controlled trials
2023 May;38(4):698-705. doi: 10.1177/02676591221076284.
Abstract
Objective: Ticagrelor may be an alternative to aspirin as it provides
robust and consistent platelet inhibition. However, the effect of ticagrelor
treatment in patients undergoing coronary artery bypass grafting (CABG) has not
been well confirmed. We conducted a meta-analysis to appraise whether ticagrelor
therapy affects outcomes in CABG patients.
Methods: We searched PubMed, Embase, EBSCO, and Cochrane databases from
its inception up to 4 December 2020 for randomized controlled trials that
assessed ticagrelor versus non-ticagrelor in patients undergoing CABG. The
primary outcome was the incidence of saphenous vein graft (SVG) occlusion at 1
year after CABG. Secondary outcomes were SVG occlusion at 7 days, major adverse
cardiovascular events (MACE), and bleeding requiring reoperation.
Results: Seven trials including 4305 patients (2153 randomized to
ticagrelor therapy and 2152 to non-ticagrelor therapy) were included.
One-hundred and thirty of 1140 patients (11.4%) randomized to the ticagrelor
group versus 175 of 1220 patients (14.3%) randomized to the non-ticagrelor
group experienced SVG occlusion at 1 year after CABG. Compared to the control
group, ticagrelor therapy yielded a significantly lower risk of SVG occlusion
[RR 0.79 (0.64-0.97), p = 0.03]. In the subgroup analysis,
ticagrelor plus aspirin compared with aspirin alone did not decrease the risk
of SVG occlusion after 1 year [RR 0.65 (0.40-1.07), p = 0.09].
There was no difference in the incidence of SVG occlusion at 7 days [RR 0.67
(0.42-1.06), p = 0.09], MACE up to 1 year [RR 0.99 (0.81-1.21), p =
0.90], or bleeding requiring reoperation [RR 1.16 (0.80-1.70), p =
0.44].
Conclusions: Compared with non-ticagrelor therapy, ticagrelor decreased the
risk of saphenous vein graft occlusion after 1 year in patients undergoing
elective CABG with saphenous vein grafting.
Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.
In God we trust